A Pilot for enabling certain Medical Cannabis Export Rights
The Israeli Ministry of Health (“MOH“) has been implementing since 2016 a precedential and revolutionary reform regarding medical cannabis, which regulates all phases of the medical cannabis process, starting from cultivation and up the sale of medical cannabis products by licenses pharmacists (the “Reform“). See our previous legal update in the matter .
Although approved in principal by the Israeli parliament during 2019, the export of medical cannabis is not yet fully regulated by the MOH and other related governmental authorities. Hence, in practice export of medical cannabis was not permitted (except for ad-hoc specific approvals).
Notwithstanding, on October 4, 2020, the MOH issued a pilot program, which will be in effect until the end of 2020, pursuant to which a number of Israeli medical cannabis companies ( BOL, Univo, Seach, Canndoc, Panaxia, Together Pharma, Tikun Olam, MediCane and Better) will be granted a permit to export their products in consideration for which these companies will offer patients a price reduction to certain of their products (see link detailing the products and the proposed reduced prices), all while ensuring a suitable supply for the local market. The MOH noted that if the suitable supply and low prices are maintained, the right to export shall be maintained following the expiry of the pilot period.
For additional information please contact your GKH attorney or one of the following Adv. Hili Cohen, partner and head of life sciences department (Hili@gkh-law.com) Adv. Tami Fishman, partner (Tamif@gkh-law.com), or Adv. Ofir Goldstein (Ofirg@Gkh-Law.Com).
